Intellipharmaceutics International Inc. (IPCI)

[WeeZuhl]

That was out before the big run yesterday afternoon.

You've got it backwards. The venlafaxine approval was out mid day before the run and the NASDAQ delisting notice came after hours. Effexor XR is a good drug and should eventually help the IPCI bottom line, but face it, a drug that costs a quarter ($0.25) per capsule and already has eleven competitors is not going to do much for the current SP or save the company from delisting. Now we know why the approval PR did not come yesterday. IPCI will try to bury the after hours NASDAQ delisting PR yesterday with the venlafaxine approval PR this morning. Both are old news by now, so it should be okay for them. Look for some volatility but not much SP change in either direction by EOD.


Stay tuned for the next pump: Nasal/oral HAL study results will be described in a PR as a great success, but no data will be revealed to prove it is true.